Literature DB >> 28581487

EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK- anaplastic large-cell lymphoma.

Janine Schmidt1, Irina Bonzheim1, Julia Steinhilber1, Ivonne A Montes-Mojarro1, Carlos Ortiz-Hidalgo2, Wolfram Klapper3, Falko Fend1, Leticia Quintanilla-Martínez1.   

Abstract

Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is characterized by expression of oncogenic ALK fusion proteins due to the translocation t(2;5)(p23;q35) or variants. Although genotypically a T-cell lymphoma, ALK+ ALCL cells frequently show loss of T-cell-specific surface antigens and expression of monocytic markers. C/EBPβ, a transcription factor constitutively overexpressed in ALK+ ALCL cells, has been shown to play an important role in the activation and differentiation of macrophages and is furthermore capable of transdifferentiating B-cell and T-cell progenitors to macrophages in vitro. To analyze the role of C/EBPβ for the unusual phenotype of ALK+ ALCL cells, C/EBPβ was knocked down by RNA interference in two ALK+ ALCL cell lines, and surface antigen expression profiles of these cell lines were generated using a Human Cell Surface Marker Screening Panel (BD Biosciences). Interesting candidate antigens were further analyzed by immunohistochemistry in primary ALCL ALK+ and ALK- cases. Antigen expression profiling revealed marked changes in the expression of the activation markers CD25, CD30, CD98, CD147, and CD227 after C/EBPβ knockdown. Immunohistochemical analysis confirmed a strong, membranous CD147 (EMMPRIN) expression in ALK+ ALCL cases. In contrast, ALK- ALCL cases showed a weaker CD147 expression. CD274 or PD-L1, an immune inhibitory receptor ligand, was downregulated after C/EBPβ knockdown. PD-L1 also showed stronger expression in ALK+ ALCL compared with ALK- ALCL, suggesting an additional role of C/EBPβ in ALK+ ALCL in generating an immunosuppressive environment. Finally, no expression changes of T-cell or monocytic markers were detected. In conclusion, surface antigen expression profiling demonstrates that C/EBPβ plays a critical role in the activation state of ALK+ ALCL cells and reveals CD147 and PD-L1 as important downstream targets. The multiple roles of CD147 in migration, adhesion, and invasion, as well as T-cell activation and proliferation suggest its involvement in the pathogenesis of ALCL.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28581487     DOI: 10.1038/labinvest.2017.54

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  48 in total

1.  Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.

Authors:  Jonathan Juco; Jeannine T Holden; Karen P Mann; Lloyd G Kelley; Shiyong Li
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

2.  Anaplastic large cell lymphoma: twenty-five years of discovery.

Authors:  Marsha C Kinney; Russell A Higgins; Edward A Medina
Journal:  Arch Pathol Lab Med       Date:  2011-01       Impact factor: 5.534

3.  Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells.

Authors:  H Guo; S Zucker; M K Gordon; B P Toole; C Biswas
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

4.  NPM-ALK-dependent expression of the transcription factor CCAAT/enhancer binding protein beta in ALK-positive anaplastic large cell lymphoma.

Authors:  Leticia Quintanilla-Martinez; Stefania Pittaluga; Cornelius Miething; Margit Klier; Martina Rudelius; Theresa Davies-Hill; Natasa Anastasov; Antonio Martinez; Angelica Vivero; Justus Duyster; Elaine S Jaffe; Falko Fend; Mark Raffeld
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

5.  The expression of myeloid antigens CD13 and/or CD33 is a marker of ALK+ anaplastic large cell lymphomas.

Authors:  Ian M Bovio; Robert W Allan
Journal:  Am J Clin Pathol       Date:  2008-10       Impact factor: 2.493

6.  Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase.

Authors:  H Kataoka; R DeCastro; S Zucker; C Biswas
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

7.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.

Authors:  S W Morris; M N Kirstein; M B Valentine; K G Dittmer; D N Shapiro; D L Saltman; A T Look
Journal:  Science       Date:  1994-03-04       Impact factor: 47.728

8.  S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis.

Authors:  Toshihiko Hibino; Masakiyo Sakaguchi; Shoko Miyamoto; Mami Yamamoto; Akira Motoyama; Junichi Hosoi; Tadashi Shimokata; Tomonobu Ito; Ryoji Tsuboi; Nam-Ho Huh
Journal:  Cancer Res       Date:  2012-11-07       Impact factor: 12.701

9.  Identification of C/EBPβ target genes in ALK+ anaplastic large cell lymphoma (ALCL) by gene expression profiling and chromatin immunoprecipitation.

Authors:  Irina Bonzheim; Martin Irmler; Margit Klier-Richter; Julia Steinhilber; Nataša Anastasov; Sabine Schäfer; Patrick Adam; Johannes Beckers; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

Review 10.  The role of EMMPRIN in T cell biology and immunological diseases.

Authors:  Jennifer Nancy Hahn; Deepak Kumar Kaushik; V Wee Yong
Journal:  J Leukoc Biol       Date:  2015-05-14       Impact factor: 4.962

View more
  7 in total

1.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

2.  Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection.

Authors:  Saiaditya Badeti; Qingkui Jiang; Alireza Naghizadeh; Hsiang-Chi Tseng; Yuri Bushkin; Salvatore A E Marras; Annuurun Nisa; Sanjay Tyagi; Fei Chen; Peter Romanienko; Ghassan Yehia; Deborah Evans; Moises Lopez-Gonzalez; David Alland; Riccardo Russo; William Gause; Lanbo Shi; Dongfang Liu
Journal:  Cell Biosci       Date:  2022-06-11       Impact factor: 9.584

Review 3.  Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies.

Authors:  Kamila Polgárová; Pavel Otáhal; Cyril Šálek; Robert Pytlík
Journal:  Front Oncol       Date:  2022-05-06       Impact factor: 5.738

4.  CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling.

Authors:  Binbin Yu; Yan Zhang; Kailiu Wu; Lizhen Wang; Yingying Jiang; Wantao Chen; Ming Yan
Journal:  J Cell Mol Med       Date:  2018-11-12       Impact factor: 5.310

5.  CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.

Authors:  Ivonne-Aidee Montes-Mojarro; Julia Steinhilber; Christoph M Griessinger; Achim Rau; Ann-Kathrin Gersmann; Ursula Kohlhofer; Petra Fallier-Becker; Huan-Chang Liang; Ute Hofmann; Mathias Haag; Wolfram Klapper; Elke Schaeffeler; Bernd J Pichler; Matthias Schwab; Falko Fend; Irina Bonzheim; Leticia Quintanilla-Martinez
Journal:  Leukemia       Date:  2022-06-08       Impact factor: 12.883

Review 6.  The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL).

Authors:  Ivonne A Montes-Mojarro; Julia Steinhilber; Irina Bonzheim; Leticia Quintanilla-Martinez; Falko Fend
Journal:  Cancers (Basel)       Date:  2018-04-04       Impact factor: 6.639

7.  CD147 Expression Is Associated with Tumor Proliferation in Bladder Cancer via GSDMD.

Authors:  Junming Peng; Hongtao Jiang; Jinan Guo; Jiansheng Huang; Qian Yuan; Jing Xie; Kefeng Xiao
Journal:  Biomed Res Int       Date:  2020-02-20       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.